Cargando…
Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study
INTRODUCTION: Increased mortality has been reported in the Latin American population. The objective is to compare the clinical characteristics and outcome of Latin American and Spanish populations in a cohort of patients hospitalized with COVID-19 during the first year of the pandemic. METHODS: We r...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043505/ https://www.ncbi.nlm.nih.gov/pubmed/35476212 http://dx.doi.org/10.1007/s40121-022-00623-x |
_version_ | 1784694895484600320 |
---|---|
author | Alonso, Rodrigo Camon, Ana M. Cardozo, Celia Albiach, Laia Agüero, Daiana Marcos, M. Angeles Ambrosioni, Juan Bodro, Marta Chumbita, Mariana de la Mora, Lorena Garcia-Pouton, Nicole Dueñas, Gerard Hernandez-Meneses, Marta Inciarte, Alexy Cuesta, Genoveva Meira, Fernanda Morata, Laura Puerta-Alcalde, Pedro Herrera, Sabina Tuset, Montse Castro, Pedro Prieto-Gonzalez, Sergio Mensa, Josep Martínez, José Antonio Sanjuan, Gemma Nicolas, J. M. del Rio, A. Vila, Jordi Garcia, Felipe Garcia-Vidal, Carolina Soriano, Alex |
author_facet | Alonso, Rodrigo Camon, Ana M. Cardozo, Celia Albiach, Laia Agüero, Daiana Marcos, M. Angeles Ambrosioni, Juan Bodro, Marta Chumbita, Mariana de la Mora, Lorena Garcia-Pouton, Nicole Dueñas, Gerard Hernandez-Meneses, Marta Inciarte, Alexy Cuesta, Genoveva Meira, Fernanda Morata, Laura Puerta-Alcalde, Pedro Herrera, Sabina Tuset, Montse Castro, Pedro Prieto-Gonzalez, Sergio Mensa, Josep Martínez, José Antonio Sanjuan, Gemma Nicolas, J. M. del Rio, A. Vila, Jordi Garcia, Felipe Garcia-Vidal, Carolina Soriano, Alex |
author_sort | Alonso, Rodrigo |
collection | PubMed |
description | INTRODUCTION: Increased mortality has been reported in the Latin American population. The objective is to compare the clinical characteristics and outcome of Latin American and Spanish populations in a cohort of patients hospitalized with COVID-19 during the first year of the pandemic. METHODS: We retrospectively analysed all the Latin American patients (born in South or Central America) hospitalized in our centre from February 2020 to February 2021 and compared them with an age- and gender-matched group of Spanish subjects. Variables included were demographics, co-morbidities, clinical and analytical parameters at admission and treatment received. The primary outcomes were ICU admission and mortality at 60 days. A conditional regression analysis was performed to evaluate the independent baseline predictors of both outcomes. RESULTS: From the 3216 patients in the whole cohort, 216 pairs of case-controls (Latin American and Spanish patients, respectively) with same age and gender were analysed. COPD was more frequent in the Spanish group, while HIV was more prevalent in the Latin American group. Other co-morbidities showed no significant difference. Both groups presented with similar numbers of days from symptom onset, but the Latin American population had a higher respiratory rate (21 vs. 20 bpm, P = 0.041), CRP (9.13 vs. 6.22 mg/dl, P = 0.001), ferritin (571 vs. 383 ng/ml, P = 0.012) and procalcitonin (0.10 vs. 0.07 ng/ml, P = 0.020) at admission and lower cycle threshold of PCR (27 vs. 28.8, P = 0.045). While ICU admission and IVM were higher in the Latin American group (17.1% vs. 13% and 9.7% vs. 5.1%, respectively), this was not statistically significant. Latin American patients received remdesivir and anti-inflammatory therapies more often, and no difference in the 60-day mortality rate was found (3.2% for both groups). CONCLUSION: Latin American patients with COVID-19 have more severe disease than Spanish patients, requiring ICU admission, antiviral and anti-inflammatory therapies more frequently. However, the mortality rate was similar in both groups. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-022-00623-x. |
format | Online Article Text |
id | pubmed-9043505 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-90435052022-04-27 Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study Alonso, Rodrigo Camon, Ana M. Cardozo, Celia Albiach, Laia Agüero, Daiana Marcos, M. Angeles Ambrosioni, Juan Bodro, Marta Chumbita, Mariana de la Mora, Lorena Garcia-Pouton, Nicole Dueñas, Gerard Hernandez-Meneses, Marta Inciarte, Alexy Cuesta, Genoveva Meira, Fernanda Morata, Laura Puerta-Alcalde, Pedro Herrera, Sabina Tuset, Montse Castro, Pedro Prieto-Gonzalez, Sergio Mensa, Josep Martínez, José Antonio Sanjuan, Gemma Nicolas, J. M. del Rio, A. Vila, Jordi Garcia, Felipe Garcia-Vidal, Carolina Soriano, Alex Infect Dis Ther Original Research INTRODUCTION: Increased mortality has been reported in the Latin American population. The objective is to compare the clinical characteristics and outcome of Latin American and Spanish populations in a cohort of patients hospitalized with COVID-19 during the first year of the pandemic. METHODS: We retrospectively analysed all the Latin American patients (born in South or Central America) hospitalized in our centre from February 2020 to February 2021 and compared them with an age- and gender-matched group of Spanish subjects. Variables included were demographics, co-morbidities, clinical and analytical parameters at admission and treatment received. The primary outcomes were ICU admission and mortality at 60 days. A conditional regression analysis was performed to evaluate the independent baseline predictors of both outcomes. RESULTS: From the 3216 patients in the whole cohort, 216 pairs of case-controls (Latin American and Spanish patients, respectively) with same age and gender were analysed. COPD was more frequent in the Spanish group, while HIV was more prevalent in the Latin American group. Other co-morbidities showed no significant difference. Both groups presented with similar numbers of days from symptom onset, but the Latin American population had a higher respiratory rate (21 vs. 20 bpm, P = 0.041), CRP (9.13 vs. 6.22 mg/dl, P = 0.001), ferritin (571 vs. 383 ng/ml, P = 0.012) and procalcitonin (0.10 vs. 0.07 ng/ml, P = 0.020) at admission and lower cycle threshold of PCR (27 vs. 28.8, P = 0.045). While ICU admission and IVM were higher in the Latin American group (17.1% vs. 13% and 9.7% vs. 5.1%, respectively), this was not statistically significant. Latin American patients received remdesivir and anti-inflammatory therapies more often, and no difference in the 60-day mortality rate was found (3.2% for both groups). CONCLUSION: Latin American patients with COVID-19 have more severe disease than Spanish patients, requiring ICU admission, antiviral and anti-inflammatory therapies more frequently. However, the mortality rate was similar in both groups. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-022-00623-x. Springer Healthcare 2022-04-27 2022-06 /pmc/articles/PMC9043505/ /pubmed/35476212 http://dx.doi.org/10.1007/s40121-022-00623-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Alonso, Rodrigo Camon, Ana M. Cardozo, Celia Albiach, Laia Agüero, Daiana Marcos, M. Angeles Ambrosioni, Juan Bodro, Marta Chumbita, Mariana de la Mora, Lorena Garcia-Pouton, Nicole Dueñas, Gerard Hernandez-Meneses, Marta Inciarte, Alexy Cuesta, Genoveva Meira, Fernanda Morata, Laura Puerta-Alcalde, Pedro Herrera, Sabina Tuset, Montse Castro, Pedro Prieto-Gonzalez, Sergio Mensa, Josep Martínez, José Antonio Sanjuan, Gemma Nicolas, J. M. del Rio, A. Vila, Jordi Garcia, Felipe Garcia-Vidal, Carolina Soriano, Alex Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study |
title | Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study |
title_full | Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study |
title_fullStr | Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study |
title_full_unstemmed | Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study |
title_short | Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study |
title_sort | clinical presentation and outcome of covid-19 in a latin american versus spanish population: matched case-control study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043505/ https://www.ncbi.nlm.nih.gov/pubmed/35476212 http://dx.doi.org/10.1007/s40121-022-00623-x |
work_keys_str_mv | AT alonsorodrigo clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT camonanam clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT cardozocelia clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT albiachlaia clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT aguerodaiana clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT marcosmangeles clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT ambrosionijuan clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT bodromarta clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT chumbitamariana clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT delamoralorena clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT garciapoutonnicole clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT duenasgerard clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT hernandezmenesesmarta clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT inciartealexy clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT cuestagenoveva clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT meirafernanda clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT moratalaura clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT puertaalcaldepedro clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT herrerasabina clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT tusetmontse clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT castropedro clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT prietogonzalezsergio clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT mensajosep clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT martinezjoseantonio clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT sanjuangemma clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT nicolasjm clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT delrioa clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT vilajordi clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT garciafelipe clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT garciavidalcarolina clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT sorianoalex clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy AT clinicalpresentationandoutcomeofcovid19inalatinamericanversusspanishpopulationmatchedcasecontrolstudy |